ArticleNature communications2022
RNA polymerase II pausing factor NELF in CD8
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Diverse roles of YTHDC1 in chromatin and blood cancers.Frontiers in genetics · 2026Review
- Nelfb promotes dermal white adipose tissue formation through RNA polymerase II-mediated adipogenic gene regulation.Development (Cambridge, England) · 2025Article
- Decoding heterogeneous single-cell perturbation responses.Nature cell biology · 2025Article
- Myeloid cells meet CD8Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Epigenetic regulation of tumor immunity.The Journal of clinical investigation · 2024Review
- Decoding Heterogenous Single-cell Perturbation Responses.bioRxiv : the preprint server for biology · 2023Article
- Dependency of NELF-E-SLUG-KAT2B epigenetic axis in breast cancer carcinogenesis.Nature communications · 2023Article
- BRCA1 deficiency in mature CD8Journal for immunotherapy of cancer · 2023Article
- Strategies to reinvigorate exhausted CD8Frontiers in immunology · 2023Review
- m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma.Frontiers in pharmacology · 2022Article
- Integrative pan-cancer analysis and clinical characterization of the N7-methylguanosine (m7G) RNA modification regulators in human cancers.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
T cell factor 1 (TCF1) is required for memory and stem-like CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.